Vous avez cherché: hyperplasia (Anglais - Maltais)

gingival hyperplasia
iperplasja tal-ħniek

benign prostatic hyperplasia
iperplażja beninna tal-prostata

untreated endometrial hyperplasia.
iperplasija endometrijali mhux ikkurata.

hyperplasia endometrial, vulvovaginal pruritus
iperplejżja ta 'l- endometriju, ħakk vulvo - • vaġinali

pancreatitis, gastritis, gingival hyperplasia
pankreatite, gastrite, iperplasja tal-ħniek

benign prostatic hyperplasia in adult men
iperplażja beninna tal-prostata fl-irġiel adulti

for the treatment of benign prostatic hyperplasia
għall-kura tal-iperplażja beninna tal-prostata

a history of endometrial hyperplasia (see below)
passat ta 'iperplejżja ta' l- endometriju (ara hawn taħt) •

the biliary hyperplasia regressed upon cessation of dosing.
l-iperplasija biljari marret lura kif twaqqaf l-iddożar.

endometrial hyperplasia may be a precursor to endometrial cancer.
l-iperplasja endometrijali tista’ tkun prekursur għal kanċer endometrijali.

these changes should not be confused with endometrial hyperplasia.
dawn il-bidliet ma għandhomx jiġu mfixkla ma’ iperplażja endometrijali.

nasal bone hyperplasia has not been observed with ambrisentan in mice or dogs.
ma ġietx osservata iperplasja ta 'l- għadma ta' l- imnieħer b' ambrisentan fi ġrieden jew klieb.

hepatotoxicity, hepatic failure, nodular regenerative hyperplasia, portal hypertension
tossiċità tal-fwied, insuffiċjenza tal- fwied, iperplasija riġenerattiva nodulari, pressjoni portali għolja

in a carcinogenicity study, male rats developed leydig cell tumours and hyperplasia.
fi studju dwar il-karċinoġeneċità, il-firien irġiel żviluppaw tumuri taċ-ċelluli leydig u iperplasija.

urinary symptoms associated with a common condition called benign prostatic hyperplasia.
sintomi urinarju assoċjati ma’ kundizzjoni komuni li tissejjaħ iperplażja beninna tal-prostata.

treatment of the signs and symptoms of benign prostatic hyperplasia in adult males.
il-kura tas-sinjali u s-sintomi tal-iperplażja beninna tal-prostata fl-irġiel adulti.

compared to placebo, raloxifene was not associated with spotting or bleeding or endometrial hyperplasia.
meta mqabbel mal-plaċebo, raloxifene ma kienx assoċjat ma’ tbabar jew tnixxija ta’ demm, jew ħxuna ta’ l- endometriju.

data suggest a dose-response relationship between unopposed-cee and risk of hyperplasia.
id- dejta tissuġġerixxi li hemm relazzjoni dipendenti fuq id- doża bejn is- cee mhux opponut u r- riskju ta ’ l- iperplażja.

in addition, reversible changes to the endometrium are denoted paec and are different from endometrial hyperplasia.
barra minn hekk, bidliet riversibbli lill-endometriju huma indikati bħala paec u huma differenti minn iperplażja endometrijali.

16 simultaneously to patients with benign prostatic hyperplasia (bph) stabilized on doxazosin therapy.
fi tlett studji speċifiċi għal interazzjoni bejn żewġ prodotti mediċinali, alpha blocker doxazocin (4mg u 8mg) u sildenafil (25mg, 50mg u 100mg) ġew amministrati fl- istess ħin lil pazjenti bi tkabbir benin tal- prostata (bph), stabilizzati fuq kura ta ’ doxazocin.